HOUSTON, Texas, USA, April 26, 2016 – The University of Texas MD Anderson Cancer
Center has signed a deal with Elekta (EKTA-B.ST) to acquire Elekta
Infinity™ (https://www.elekta.com/infinity) linear accelerators, brachytherapy
afterloaders as well as software and service.
Bill Yaeger, Elekta’s Executive Vice President, Region North America, says: “As
a world-renowned cancer center, MD Anderson has been a technology leader in
managing the disease. In addition to being one of the first U.S. medical centers
to acquire Elekta’s new Leksell Gamma Knife®
Icon™ (http://www.careforthebrain.com/) brain radiosurgery system, MD Anderson
is also part of the consortium to develop the world’s first high-field MR-guided
linear accelerator. We are proud that it has chosen us again in the expansion of
its facilities in Texas. Both organizations share a commitment to quality and
the best care possible for patients.”
The order, for four Infinity treatment systems, will also include Elekta’s high
-resolution beam shaping solution, the Agility™ (https://www.elekta.com/agility)
160-leaf multi-leaf collimator.
The deal also includes four high-dose-rate (HDR) brachytherapy afterloaders and
Oncentra® Brachy (https://www.elekta.com/brachytherapy/oncentra-brachy-treatment
-planning.html) treatment planning; MOSAIQ® (https://www.elekta.com/software
-solutions/care-management/mosaiq-radiation-oncology.html) Oncology Information
System (OIS); Active Breathing
Coordinator™ (https://www.elekta.com/radiotherapy/treatment-solutions/motion
-management/active-breathing-coordinator.html?utm_source=active-breathing
-coordinator&utm_medium=redirect&utm_campaign=redirects) units; as well as
service for the hardware and software.
The order will be booked in Elekta’s fourth quarter, fiscal year 2015-16.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on April 26, 2016.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.
